
PharmEC REACH study: reaching methadone users attending community pharmacies with HCV
Assessing the effectiveness, feasibility, and cost-effectiveness of nurse-led testing and treatment of hepatitis C in community pharmacies, for people on opiate substitution therapy.
Objective
The advent of direct acting antiviral medication and GP management of uncomplicated cases of hepatitis C has made access to treatment easier than ever.
Despite advances, there are still at-risk people however who, for many different reasons, are not engaged with health care services. New models of care need to be explored in a bid to offer testing and treatment to these harder-to-reach populations. This project aims to assess another possible pathway for people on opioid substitution therapy to learn about, access testing and treatment for hepatitis C through community pharmacies.
Timeline
2021–2023.
Approach
From 2019 to 2021 an international, multicentre trial was completed assessing the effectiveness and feasibility of nurse-led HCV counselling, testing and treatment for OST clients in community pharmacies (The REACH study). The trial engaged 40 community pharmacies dispensing opioid substitution therapy (OST) across 3 countries: Australia, Scotland and Wales.
Researchers from the University of Dundee, University of Wales, Monash University and The Burnet Institute were able to demonstrate that targeted counselling, testing and treatment in community pharmacies was highly successful in:
- delivering more tests
- more cures
- a higher level of engagement in health services in this population.
To further develop this concept into a comprehensive public health program, three further bodies of work have been undertaken by researchers at the Burnet Institute from 2022 to 2023. These include a qualitative analysis to explore acceptability, a cost-effectiveness analysis to assess the efficiency, and stakeholder engagement to assess the feasibility of this nurse-led community pharmacy model of care.
The information from these analyses will contribute to a comprehensive plan for the scale up of counselling, testing, and treatment of OST clients visiting community pharmacies.
Resources
-
Hepatitis C Pharmacy Support Toolkit
Hepatitis C Pharmacy Support Toolkit [PDF 922.2 kB] -
Hepatitis C Pharmacy Support One Page Summary
Hepatitis C Pharmacy Support One Page Summary [PDF 131.0 kB]
Partners
Funding partners
Community Grants Hub–Australian Government
Collaborators
Prof Suzanne Nielsen, Monash Addiction Research Centre
Project contacts

Professor Joseph (Joe) Doyle
Deputy Program Director, Disease Elimination; Co-Head, Infectious Diseases Clinical Research; President, Hepatitis Australia; NHMRC Clinical Research Fellow
Team members

Professor Joseph (Joe) Doyle
Deputy Program Director, Disease Elimination; Co-Head, Infectious Diseases Clinical Research; President, Hepatitis Australia; NHMRC Clinical Research Fellow

Kate Allardice RN RM (she/her)
Senior Research Nurse – Disease Elimination

Dr Jacqui Richmond
Program Manager, Workforce Development and Health Service Delivery, EC Australia

Associate Professor Peter Higgs
Principal Research Fellow; Honorary Associate Professor, Department of Public Health, La Trobe University

Dr Joshua Ginnane
Senior Research Officer
Project team

Kate Allardice RN RM (she/her)
Senior Research Nurse – Disease Elimination

Professor Joseph (Joe) Doyle
Deputy Program Director, Disease Elimination; Co-Head, Infectious Diseases Clinical Research; President, Hepatitis Australia; NHMRC Clinical Research Fellow

Dr Joshua Ginnane
Senior Research Officer

Associate Professor Peter Higgs
Principal Research Fellow; Honorary Associate Professor, Department of Public Health, La Trobe University
